Current filters:  
Canada
Healthcare
Canada
Miller Thomson LLP
In 2017, the then Ontario Ministry of Health and Long-Term Care issued a Hospital Naming Directive ("Naming Directive") setting out naming criteria and approval processes that all Ontario...
Bennett Jones LLP
Growing investment in technology (AgTech) and innovation, Environment, Sustainability and Governance (ESG)...
Smart & Biggar
CIHI: On December 17, the Canadian Institute for Health Information (CIHI) published statistics on drug spending, finding that in 2018, around 40% of drug spending was...
Smart & Biggar
In November 2019, we highlighted the key proposed amendments to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and...
Smart & Biggar
On November 20, 2019, the Federal Court (FC) issued its reconsideration decision on the quantum of damages owed by Apotex for its infringement of eight Eli Lilly process...
Miller Thomson LLP
In an unprecedented move, Alberta Health Services and Alberta Health decided to conduct a complete review of the way in which health care delivered by Alberta Health Services is regulated, governed and funded.
Fasken
This bulletin provides a summary of the recent developments.
Norton Rose Fulbright Canada LLP
Health Canada received an ATI request for information on Fortekor.
Gluckstein Personal Injury Lawyers
Health agencies around the world have begun to alert the public to a new concern – the 2019 novel coronavirus (2019-nCoV), which was first identified in humans in China's Hubei province.
Fasken
The Patented Medicine Prices Review Board recently published draft Guidelines to replace the current Compendium of Policies, Guidelines and Procedures, leading up to the coming into force of the amended ...
Fasken
In preparation for the coming into force of the amended Patented Medicines Regulations, the PMPRB has published draft guidelines to replace the current Compendium of Policies, Guidelines and Procedures.
Bereskin & Parr LLP
Biotechnology companies have a long road to commercialization. Investors, shareholders and company officials often have their patience tested
Norton Rose Fulbright Canada LLP
Not all software falls within the scope of the Act and Regulations.
Osler, Hoskin & Harcourt LLP
When patents expire on a patented drug product, paving the way for generic competition, the patentee is faced with the challenge of how to replace the revenues that were achieved...
Norton Rose Fulbright Canada LLP
The Canadian pharma and life sciences space saw many developments in 2019. These included major policy initiatives and regulatory changes affecting the industry, driven in part by three high-profile
Fasken
Bill 138, the Plan to Build Ontario Together Act, which includes amendments to the Independent Health Facilities Act and Health Insurance Act, was introduced by the Ontario Minister of Finance on November 6, 2019 ...
Miller Thomson LLP
The past year has been one marked with significant change in Ontario. We have seen the introduction of new legislation including the Connecting Care Act, 2019 and policy changes which substantially restructure the health care system in the Province.
Smart & Biggar
In 2019, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. We review top developments below:...
Borden Ladner Gervais LLP
Apologies have become a standard way for health-care providers to restore a plaintiff's dignity and heal humiliations caused by error or negligence.
McCarthy Tétrault LLP
The Patented Medicine Prices Review Board ("PMPRB" or the "Board") has published Draft Guidelines for public consultation, which are intended to operationalize the...
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Upcoming Events
Tools
Font Size:
Translation
Mondaq Social Media